Gujarat Terce Laboratories Ltd vs Shree Ganesh Biotech India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Gujarat Terce Laboratories Ltd is ₹ 36.04 as of 18 May 15:30 . The P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Shree Ganesh Biotech India Ltd changed from 740.6 on March 2021 to 90 on March 2025 . This represents a CAGR of -34.40% over 5 years The Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 yearsThe Market Cap of Shree Ganesh Biotech India Ltd changed from ₹ 236.18 crore on March 2021 to ₹ 35.88 crore on March 2025 . This represents a CAGR of -31.40% over 5 years The revenue of Gujarat Terce Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 12.42 crore. This represent the decline of -100% The revenue of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ 2.4 crore as compare to the Dec '25 revenue of ₹ 1.07 crore. This represent the growth of 124.3% The ebitda of Gujarat Terce Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 1.26 crore. This represent the decline of -100% The ebitda of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ -0.15 crore as compare to the Dec '25 ebitda of ₹ 0.32 crore. This represent the decline of -146% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Shree Ganesh Biotech India Ltd changed from ₹ 0.24 crore to ₹ -0.15 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shree Ganesh Biotech India Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man.
Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs. Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

About Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Limited was incorporated on September 2, 1982, as 'S.P. Commercial Co. Limited' with the Registrar of Companies, West Bengal.
The Company got the Certificate of Commencement of Business on September 14, 1982.
The Company was incorporated with an object to carry on the business of builders, Contractors and to deal in property and also to do investment and finance business. In 2010, pursuant to a Scheme of Amalgamation, Shree Ganesh Bio-Tech (India) Private Limited was merged with S.P. Commercial Co. Limited pursuant to the order of the Hon'ble High at Calcutta dated February 15, 2010.
The entire business of Shree Ganesh Bio-Tech (India) Private Limited consisting of trading and distribution of seeds were transferred to S.P. Commercial Co. Limited.
Subsequently, Shree Ganesh Bio-Tech (India) Private Limited was dissolved pursuant to the said Scheme of Amalgamation and the name of the Company was changed to Shree Ganesh Bio-Tech (India) Limited.

FAQs for the comparison of Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd

Which company has a larger market capitalization, Gujarat Terce Laboratories Ltd or Shree Ganesh Biotech India Ltd?

Market cap of Gujarat Terce Laboratories Ltd is 28 Cr while Market cap of Shree Ganesh Biotech India Ltd is 24 Cr

What are the key factors driving the stock performance of Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd?

The stock performance of Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd?

As of May 18, 2026, the Gujarat Terce Laboratories Ltd stock price is INR ₹36.04. On the other hand, Shree Ganesh Biotech India Ltd stock price is INR ₹0.61.

How do dividend payouts of Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd compare?

To compare the dividend payouts of Gujarat Terce Laboratories Ltd and Shree Ganesh Biotech India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.